<code id='183C982222'></code><style id='183C982222'></style>
    • <acronym id='183C982222'></acronym>
      <center id='183C982222'><center id='183C982222'><tfoot id='183C982222'></tfoot></center><abbr id='183C982222'><dir id='183C982222'><tfoot id='183C982222'></tfoot><noframes id='183C982222'>

    • <optgroup id='183C982222'><strike id='183C982222'><sup id='183C982222'></sup></strike><code id='183C982222'></code></optgroup>
        1. <b id='183C982222'><label id='183C982222'><select id='183C982222'><dt id='183C982222'><span id='183C982222'></span></dt></select></label></b><u id='183C982222'></u>
          <i id='183C982222'><strike id='183C982222'><tt id='183C982222'><pre id='183C982222'></pre></tt></strike></i>

          focus

          focus

          author:knowledge    Page View:53392

          Which presentations are worth catching at ASCO this weekend? What is exon-skipping? And how do you pronounce bronchiectasis?

          This week on “The Readout LOUD,” we preview some of the research that will be presented at the American Society of Clinical Oncology conference in Chicago. We also discuss the latest news in the health and life sciences, including a milestone in lung disease R&D and a Duchenne muscular dystrophy confirmatory trial failure.  

          advertisement

          To read more about Merus’ combination therapy, go here; For more on Johnson & Johnson’s mixed data, click here; For more on Nippon Shinyaku’s Duchenne drug trial failure, go here; To read more on Insmed’s bronchiectasis treatment, click here; To sign up for STAT’s ASCO newsletter, click here.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          explore

          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more
          Paxlovid study fails to answer questions over benefit for broader groups
          Paxlovid study fails to answer questions over benefit for broader groups

          KobiWolf/BloombergPfizersaidTuesdaythatamuch-watchedstudyofitsantiviralPaxlovidinpatientswhohaveCovi

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Better Therapeutics data on benefit with GLP

          APStockYou’rereadingthewebeditionofSTAT’sHealthTechnewsletter,ourguidetohowtechnologyistransformingt